Literature DB >> 9400791

Sorsby fundus dystrophy: reevaluation of variable expressivity in patients carrying a TIMP3 founder mutation.

U Felbor1, C Benkwitz, M L Klein, J Greenberg, C Y Gregory, B H Weber.   

Abstract

Interfamilial phenotypic variations in Sorsby fundus dystrophy (SFD) have given rise to controversy as to whether SFD constitutes more than 1 nosologic entity. The recent identification of the tissue inhibitor of metalloproteinases-3 (TIMP3) as the gene causing SFD has made it possible to readdress the question of genetic and clinical heterogeneity. In this study, we have extended previous findings on a Ser181Cys founder mutation in SFD families from the British Isles and show that carriers of this mutation residing in Canada, the United States, and South Africa likewise are descendants of the British ancestor. In addition, we have reevaluated the question of variable SFD phenotypes by analyzing the available clinical data on carriers of the Ser181Cys mutation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9400791     DOI: 10.1001/archopht.1997.01100160739011

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  13 in total

1.  Clinical features of a novel TIMP-3 mutation causing Sorsby's fundus dystrophy: implications for disease mechanism.

Authors:  M Clarke; K W Mitchell; J Goodship; S McDonnell; M D Barker; I D Griffiths; N McKie
Journal:  Br J Ophthalmol       Date:  2001-12       Impact factor: 4.638

2.  Successful photodynamic therapy for subretinal neovascularisation due to Sorsby's fundus dystrophy: 1 year follow up.

Authors:  S C Wong; K C S Fong; N Lee; K Gregory-Evans; C Y Gregory-Evans
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

3.  A novel TIMP3 mutation associated with a retinitis pigmentosa-like phenotype.

Authors:  Meghan J DeBenedictis; Yosef Gindzin; Enrico Glaab; Bela Anand-Apte
Journal:  Ophthalmic Genet       Date:  2020-07-27       Impact factor: 1.803

4.  Morphologic Patterns Formed by the Anomalous Fibers Occurring Along the Anterior Capsule of the Crystalline Lens in People With the Long Anterior Zonule Trait.

Authors:  Daniel K Roberts; Yongyi Yang; Christina E Morettin; Tricia L Newman; Mary F Roberts; Jacob T Wilensky
Journal:  Anat Rec (Hoboken)       Date:  2017-02-25       Impact factor: 2.064

Review 5.  Genetic modifiers and oligogenic inheritance.

Authors:  Maria Kousi; Nicholas Katsanis
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

Review 6.  Genotype-phenotype correlations and differential diagnosis in autosomal dominant macular disease.

Authors:  A Iannaccone
Journal:  Doc Ophthalmol       Date:  2001-05       Impact factor: 2.379

7.  S156C mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis.

Authors:  Jian Hua Qi; Ganying Dai; Philip Luthert; Shyam Chaurasia; Joe Hollyfield; Bernhard H F Weber; Heidi Stöhr; Bela Anand-Apte
Journal:  J Biol Chem       Date:  2009-05-28       Impact factor: 5.157

8.  Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.

Authors:  Jian Hua Qi; Quteba Ebrahem; Mariya Ali; Alecia Cutler; Brent Bell; Nicholas Prayson; Jonathan Sears; Vera Knauper; Gillian Murphy; Bela Anand-Apte
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

9.  Clinical and biochemical effects of the E139K missense mutation in the TIMP3 gene, associated with Sorsby fundus dystrophy.

Authors:  Z Saihan; Z Li; J Rice; N A Rana; S Ramsden; P G Schlottmann; S A Jenkins; C Blyth; G C Black; N McKie; A R Webster
Journal:  Mol Vis       Date:  2009-06-15       Impact factor: 2.367

10.  The N-terminal p.(Ser38Cys) TIMP3 mutation underlying Sorsby fundus dystrophy is a founder mutation disrupting an intramolecular disulfide bond.

Authors:  Sarah Naessens; Julie De Zaeytijd; Delfien Syx; Roosmarijn E Vandenbroucke; Frédéric Smeets; Caroline Van Cauwenbergh; Bart P Leroy; Frank Peelman; Frauke Coppieters
Journal:  Hum Mutat       Date:  2019-02-06       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.